designer491
designer491 / iStockphoto.com
31 May 2018Asia-Pacific

Astellas-backed Crescendo pairs up with Zai Lab in licensing deal

UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
7 June 2018   Pharmaceutical company Astellas Pharma has filed a patent infringement claim against India-based Cipla over a drug for treating an overactive bladder.
Asia-Pacific
15 August 2018   Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.

More on this story

Americas
7 June 2018   Pharmaceutical company Astellas Pharma has filed a patent infringement claim against India-based Cipla over a drug for treating an overactive bladder.
Asia-Pacific
15 August 2018   Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.

More on this story

Americas
7 June 2018   Pharmaceutical company Astellas Pharma has filed a patent infringement claim against India-based Cipla over a drug for treating an overactive bladder.
Asia-Pacific
15 August 2018   Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.